Medical Oncologist
Medicines
T-DM1 vs continuing trastuzumab after residual disease
When invasive HER2-positive cancer remains at surgery after treatment given beforehand, switching to T-DM1 is usually recommended over continuing trastuzumab. It lowers the chance of recurrence but causes more side effects. This page compares the two honestly, explains when trastuzumab may still be chosen and suggests questions to ask your oncologist.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
On this page
- T-DM1 or trastuzumab after residual disease?
- What each option involves
- How the two compare
- The vocabulary, in plain language
- Honest realities about this choice
- Situations where continuing trastuzumab makes sense
- Questions to ask your oncologist
- What people assume about this choice
- Common questions about T-DM1 versus trastuzumab
The short answer
T-DM1 or trastuzumab after residual disease?
If you had chemotherapy and HER2-targeted treatment before surgery for HER2-positive breast cancer, and some invasive cancer was still found in the breast or lymph nodes at surgery, you have what is called residual disease. For most people in this situation, current international guidance recommends switching from trastuzumab to trastuzumab emtansine, also known as T-DM1 or Kadcyla, for fourteen cycles given every three weeks after surgery. This recommendation comes from the KATHERINE trial, which compared T-DM1 directly with continuing trastuzumab. T-DM1 roughly halved the risk of invasive cancer returning in the first few years, and longer follow-up showed that more people were alive. The trade-off is side effects. T-DM1 caused more tiredness, low platelets, raised liver enzymes and tingling in the hands and feet, and around one in five people stopped it early, usually switching back to trastuzumab to finish their treatment. Trastuzumab alone is gentler and remains a reasonable choice for some people, for example when T-DM1 is not suitable because of existing nerve damage, liver problems or low blood counts, or when it cannot be accessed. Newer trials are testing other options in this setting, so guidance may evolve. The best choice depends on your pathology report, your health, what you coped with before surgery and your own priorities, and is worth talking through carefully with your oncologist.
T-DM1 is the usual recommendation
For residual HER2-positive disease, it reduced recurrence more than trastuzumab in a large trial.
Trastuzumab is gentler
Fewer side effects, but a higher chance of the cancer coming back on average.
Switching is possible
If T-DM1 side effects are too much, many people move to trastuzumab to complete treatment.
This page gives general information only. Your team will recommend the approach that fits your pathology results and health.The two paths
What each option involves
Both are given after surgery to complete your HER2-targeted treatment.
Trastuzumab emtansine
A drip every three weeks for fourteen cycles, which takes around ten months. The first infusion is longer, with later ones often around half an hour.
Continuing trastuzumab
A drip or an injection under the skin every three weeks to complete a year of HER2-targeted treatment in total.
The injection form is quicker to give.Given alongside either
Radiotherapy and hormone therapy, where needed, can usually go ahead during either treatment.
Monitoring for both
Heart scans at intervals, plus blood tests before doses. T-DM1 needs closer checking of platelets and liver function.
Bring to each visit
- Notes on tingling or bruising
- Any breathlessness
- Your medicine list
Side by side
How the two compare
Question
T-DM1 compared with trastuzumab
Chance of recurrence
Lower with T-DM1, by about half in the early years
Long-term survival
Better with T-DM1 in long-term follow-up
Overall side effects
More with T-DM1, especially low platelets, liver changes and tingling
Stopping early
Much more common with T-DM1
Hair loss and heart effects
Uncommon with both
Words you will hear
The vocabulary, in plain language
- Residual disease
- Invasive cancer still present at surgery after treatment given beforehand.
- Pathological complete response
- No invasive cancer left at surgery, in which case trastuzumab usually continues.
- Neoadjuvant treatment
- Treatment given before surgery to shrink the cancer.
- Adjuvant treatment
- Treatment given after surgery to lower the chance of the cancer returning.
- Biosimilar
- A closely matching version of a biological medicine such as trastuzumab.
- Ejection fraction
- A measure of how well the heart pumps, checked on HER2-targeted treatment.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Being straight with you
Honest realities about this choice
This is a decision where evidence is strong, but individual circumstances still matter a great deal.
The benefit is an average
Most people in both groups of the trial stayed free of cancer. T-DM1 moved more people into that group, but it cannot promise any single person will avoid recurrence.
The brain is a separate question
In the trial, fewer people had any recurrence on T-DM1, but the brain was a slightly more common first site of return in that group. Report new headaches or neurological symptoms.
Access and funding differ
T-DM1 is usually more expensive than trastuzumab and its biosimilars, and access varies. Ask your team openly about what is realistic.
What this page cannot tell you
It cannot weigh your personal risk against your side effects. Your oncologist can, using your pathology report and health history.
When trastuzumab may be chosen
Situations where continuing trastuzumab makes sense
Although T-DM1 is usually preferred, there are good reasons your team might suggest continuing trastuzumab instead.
Existing nerve damage
If tingling or numbness from taxane chemotherapy is already troublesome, T-DM1 could make it worse.
Liver or blood problems
Pre-existing liver disease or persistently low platelets can make T-DM1 riskier.
Very small amounts of residual cancer
When the remaining cancer is tiny, the absolute gain may be smaller. Many teams still recommend T-DM1, but this can be part of a shared discussion.
Other health conditions or preferences
Frailty, other illnesses or your own informed choice can all reasonably shape the decision.
Making the decision
Questions to ask your oncologist
It is fine to take a little time to think, as long as the start of treatment is not delayed too long after surgery. These questions can help.
About your risk
How much cancer remained, were lymph nodes involved, and roughly how much would T-DM1 lower my risk compared with trastuzumab?
About side effects
Given the side effects I had before surgery, which T-DM1 effects are most likely for me, and what happens if I cannot tolerate it?
About newer evidence
Have any newer trials in residual disease changed your advice, and is a clinical trial available to me?
Commonly believed
What people assume about this choice
Residual disease means my earlier treatment was wasted.
It helped shrink the cancer and gave information that guides the next step.
T-DM1 and trastuzumab are basically the same.
T-DM1 adds a chemotherapy payload and works differently.
If I stop T-DM1 early, I have no options.
Switching to trastuzumab to finish treatment is common.
Choosing trastuzumab is always the wrong decision.
It can be a reasonable choice in certain situations.
Questions we are asked
Common questions about T-DM1 versus trastuzumab
Should pertuzumab be added after surgery if I have residual disease?
In the KATHERINE trial, T-DM1 was given on its own after surgery, and that is the usual approach for residual disease. Pertuzumab is more often continued after surgery when there was no residual cancer but the original risk was high. Your oncologist will explain the plan that fits your results.
How soon after surgery does treatment start?
Usually within a few weeks, once your wound has healed and you have recovered enough. In the trial, treatment started within about three months of surgery. Your team will schedule it alongside any radiotherapy you need.
Can I switch from T-DM1 to trastuzumab midway?
Yes. If side effects such as low platelets, liver changes or nerve damage become a problem, your team may lower the dose first, or switch you to trastuzumab to complete the planned course of HER2-targeted treatment.
Is a trastuzumab biosimilar as good as the original?
Approved biosimilars have been shown to work in a closely matching way to the original trastuzumab. If you continue trastuzumab, your team may use a biosimilar, which does not reduce the benefit of treatment.
Will I still need heart scans on T-DM1?
Yes. Both treatments target HER2, which can affect the heart, although problems are uncommon. Your heart pumping function is usually checked before starting and at regular intervals during treatment.
Does hormone receptor status change the choice?
In the trial, T-DM1 helped people with both hormone receptor-positive and hormone receptor-negative cancers. If your cancer is hormone receptor-positive, you will also have hormone therapy, which is often started during this treatment.
What about trastuzumab deruxtecan instead?
Trastuzumab deruxtecan has been compared with T-DM1 in people with high-risk residual disease. Results and approvals in this setting are still developing. Ask your oncologist whether the latest evidence changes what they recommend for you.
What if I had no treatment before surgery?
This comparison only applies to people who had treatment before surgery. If you had surgery first, your team will usually recommend chemotherapy with HER2-targeted treatment afterwards, based on the size of the cancer and lymph node involvement.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- National Cancer Institute — Trastuzumab emtansine
- European Medicines Agency — Kadcyla: product information
- Cancer Research UK — Trastuzumab emtansine (Kadcyla)
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.